A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
A phase 2 trial of Lifileucel in endometrial cancer, run by Iovance Biotherapeutics, Inc., now recruiting.
Overview
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. is a phase 2 interventional study registered as NCT06481592 by Iovance Biotherapeutics, Inc., with 60 participants planned, started 2024-10-29 and due to reach its primary completion in 2028-05. Interventions recorded: Lifileucel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Shares Iovance Biotherapeutics, Lifileucel.
- IdeaUse patient organoids to check a cell therapy will work before infusing it
Shares Iovance Biotherapeutics, Lifileucel.
- TrialC-144-01
Shares Iovance Biotherapeutics, Lifileucel.
- IdeaSelect patients for cell therapy by whether their tumour holds reactive T cells
Shares Iovance Biotherapeutics, Lifileucel.
- Key paperC-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed
Shares Iovance Biotherapeutics, Lifileucel.